Company / Interest Expense per Share
BIOCRYST PHARMACEUTICALS INC Interest Expense per Share History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense per Share
$0.56
FY2023
5-year range
$0.33 / $0.56
FY2019-FY2023
Trend
+5.7%
vs FY2022
Sector context
#9 of 43
Health Care
What the data says
BIOCRYST PHARMACEUTICALS INC's interest expense per share of $0.56 is higher than 79% of companies in the Health Care sector (FY2023). Interest Expense per Share has increased for 3 consecutive years, from $0.09 in FY2020 to $0.56 in FY2023.
Based on SEC 10-K filings.
0.56 in FY2023 with a 5-year CAGR of +44.7%. Top quartile in the Health Care sector.
Increased from $0.33 to $0.56 over the past 2 years.
Health Care sector context is included.
Interest Expense per Share over time
Growth rates
- 3-Year CAGR
- +86.6%
- 5-Year CAGR
- +44.7%
- 10-Year CAGR
- -
Sector benchmark
-94.3% below sector average
Key checks
Key Insights
- BIOCRYST PHARMACEUTICALS INC's interest expense per share has grown for 3 consecutive years.
- In FY2023, interest expense per share increased 5.7% year-over-year.
- Ranks #9 out of 43 companies in the Health Care sector.
- Lowest interest expense per share in the period was in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest Expense per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $0.56 | +5.7% |
| FY2022 | $0.53 | +61.0% |
| FY2021 | $0.33 | +281.8% |
| FY2020 | $0.09 | -15.7% |
| FY2019 | $0.10 | +15.7% |
| FY2018 | $0.09 | -23.4% |
| FY2017 | $0.12 | +31.3% |
| FY2016 | $0.09 | +22.4% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026